Efficacy

Skilarence (Dimethyl Fumarate) for Psoriasis

Skilarence, containing the active ingredient dimethyl fumarate, is an oral medication approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells leading to thick, red, scaly patches on the skin. The efficacy of Skilarence in the treatment of psoriasis has been demonstrated in several clinical trials. In these studies, Skilarence has been shown to significantly reduce the Psoriasis Area and Severity Index (PASI) score, which is a measure of the severity and extent of psoriasis, indicating an improvement in the condition of the skin.

The therapeutic effects of Skilarence are thought to be due to its anti-inflammatory and immunomodulatory properties. Patients treated with Skilarence have reported a reduction in the thickness, scaling, and redness of psoriatic plaques. Additionally, improvements in quality of life measures have also been observed, which is an important consideration in a chronic disease like psoriasis that can significantly impact daily functioning and well-being.

Ilumya (Tildrakizumab) for Psoriasis

Ilumya, with the active substance tildrakizumab, is a biologic medication administered via injection for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in the inflammatory processes of psoriasis. Clinical trials have shown that Ilumya is effective in achieving clear or almost clear skin as measured by PASI 75 (75% reduction in PASI score) and PASI 90 responses in a significant proportion of patients.

The efficacy of Ilumya has been maintained in long-term studies, with sustained responses over time, which is crucial for the management of a chronic condition like psoriasis. The treatment has been well-tolerated, with a safety profile that supports its use in the long-term management of psoriasis. The ability of Ilumya to provide sustained symptom control with infrequent dosing (typically every 12 weeks after initial doses) is beneficial for patient adherence and quality of life.